Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: Results from the women's health initiative randomized trial

Journal of Bone and Mineral Research

Volumn 21, Issue 6, 2006, Pages 817-828

  Jackson, Rebecca D ^a   Wactawski Wende, Jean ^b   LaCroix, Andrea Z ^c   Pettinger, Mary ^c   Yood, Robert A ^d   Watts, Nelson B ^e   Robbins, John A ^f   Lewis, Cora E ^g   Beresford, Shirley A A ^h   Ko, Marcia G ⁱ   Naughton, Michelle J ^j   Satterfield, Suzanne ^k   Bassford, Tamsen ^l  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ MAYO CLINIC   (United States)

^j WAKE FOREST SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^l UNIVERSITY OF ARIZONA   (United States)

more..

Author keywords

BMD; Clinical trial; Estrogen; Fracture; Hormone therapy; Postmenopause; Women's Health Initiative

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CONJUGATED ESTROGEN;

ADULT; AGE; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; ETHNIC GROUP; FALLING; FEMALE; FRACTURE; FRACTURE REDUCTION; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; INCIDENCE; MAJOR CLINICAL STUDY; OVARIECTOMY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PREDICTION; QUESTIONNAIRE; RACE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; WOMEN'S HEALTH;

AGED; BONE DENSITY; ESTROGENS, CONJUGATED (USP); FEMALE; FRACTURES, BONE; HUMANS; HYSTERECTOMY; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 33646865086     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060312     Document Type: Article

References (23)

1. Cummings SR, Melton LJ III 2002 Epidemiology and outcomes of osteoporosis fractures. Lancet 359:1761-1767.
2. www.healthypeople.gov/publications. Accessed April 11, 2006.
3. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
4. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB 2003 Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 290:1729-1738.
5. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712.
6. The Women's Health Initiative Study Group 1998 Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19:61-109.
7. Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR 2003 The Women's Health Initiative postmenopausal hormone trials: Overview and baseline characteristics of participants. Ann Epidemiol 13:S78-S86.
8. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, Daugherty S 2003 Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 13:8122-8128.
9. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T 1999 Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol 9:178-187.
10. Black DM, Steinbuch M. Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O 2001 An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12:519-528.
11. Jackson RD, LaCroix A, Cauley JA, McGowan J 2003 The Women's Health Initiative Calcium-vitamin D Trial: Overview and baseline characteristics of participants. Ann Epidemiol 13:898-106.
12. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N 1994 Perspective: The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141.
13. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR 1995 Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 122:9-16.
14. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR 1980 Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195-1198.
15. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Seeman E, Nicholson GC 2004 Hormone therapy and risk of non-vertebral fracture: Geelong osteoporosis study. Osteoporos Int 15:434-438.
16. Banks E, Beral V, Reeves G, Balkwill A, Barnes I 2004 Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291:2212-2220.
17. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A 2002 Meta-analyses of therapies for postmenopausal osteoporosis V. Meta-Analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 23:529-539.
18. Torgerson DJ, Bell-Syer SEM 2001 Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. JAMA 285:2891-2897.
19. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD 2002 Postmenopausal hormone replacement therapy. JAMA 288:872-881.
20. Longcope C, Baker S 1993 Androgen and estrogen dynamics: Relationships with age, weight and menopausal status. J Clin Endocrinol Metab 76:601-604.
21. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier P, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340.
22. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
23. Kanis JA, Johnell O, Black DM, Downs RW, Sarkar S, Fuerst T, Secrest RJ, Pavo I 2003 Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A re-analysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 22:293-300.